
Phosphatidylinositol 3-kinase (PI3K) inhibitors are a promising class of targeted oncologic therapies but metabolic toxicities, particularly hyperglycemia, limit their use. We conducted a meta-analysis of phase II/III randomized controlled trials to quantify the incidence and relative risk (RR) of hyperglycemia associated with PI3K inhibition in cancer patients. A systematic search of PubMed through August 2025 identified 16 eligible trials, comprising approximately 5,000 patients. Among patients treated with PI3K inhibitors, the summary incidence of all-grade hyperglycemia was 44.4% (95% CI: 33.3-55.5%), while high-grade hyperglycemia occurred in 18.6% (95% CI: 9.7-27.6%). PI3K inhibitor was associated with an increased risk of hyperglycemia with an RR of 3.43 (95% CI: 2.42-4.87, p < 0.001) for all-grade events and 9.79 (95% CI: 5.77-16.62, p < 0.001) for high-grade events. Subgroup analysis showed that cancer type significantly moderated the incidence of high-grade hyperglycemia (p = 0.01). Subgroup analyses also showed significant variation among PI3K inhibitor subtypes (p < 0.01), with PI3K alpha-selective inhibitors conferring the greatest relative risk, particularly for severe hyperglycemia, whereas dual PI3K/mTOR inhibitors showed comparatively lower risk. These findings have demonstrated that PI3K inhibitors are associated with a significantly increased risk of hyperglycemia. Proactive monitoring and early intervention are essential to mitigate adverse outcomes and optimize therapeutic benefit.
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal despite advances in systemic and biomarker-directed therapy. Treatment resistance reflects not only tumor genotype but also desmoplasia, vascular dysfunction, immune suppression, metabolic adaptation, and evolutionary plasticity. This review integrates signaling dependency, ecosystem architecture, and adaptive evolution into an ecosystem-adaptive framework to explain therapeutic failure in PDAC and proposes four candidate ecosystem states: desmoplastic exclusion, myeloid dominance, hypoxic-metabolic adaptation, and immune-interface organization. These dynamic states may influence therapeutic exposure and resistance beyond conventional molecular classification. Prospective validation could support biomarker development, therapeutic stratification, rational treatment combinations, and treatment sequencing in pancreatic cancer.
Oral squamous cell carcinoma (OSCC) develops in a microbe-rich, injury-prone mucosa in which coagulation, inflammation, and tissue repair are closely coupled. Tumor and host cells can activate tissue factor-thrombin signaling, platelets, fibrin turnover, extracellular vesicles, and neutrophil extracellular traps, thereby reshaping myeloid-cell recruitment, cytotoxic immunity, angiogenesis, and invasion. However, local procoagulant biology does not necessarily predict systemic venous thromboembolism. We therefore organize the evidence using a compartmentalized immunothrombosis model that distinguishes intratumoral coagulation-immune remodeling, systemic thrombosis, and treatment-dependent perioperative events. Direct OSCC studies support several components of this network, but much of the evidence linking coagulation to immune escape and treatment response remains preclinical or extrapolated from other tumors. Circulating D-dimer, fibrinogen, platelet indices, and inflammatory ratios show prognostic associations, yet their incremental value beyond established clinicopathologic factors has not been established. Anticoagulant, antiplatelet, protease-activated receptor, podoplanin-CLEC-2, fibrinolytic, and NET-directed strategies are biologically plausible but should not be used as OSCC treatment without a standard indication or clinical trial. Future studies should pair longitudinal blood measurements with spatial tumor profiling and match interventions to a verified mechanism, anatomical compartment, and safe treatment window.